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The importance of counterregulatory mechanisms trig•
gered by arterial vasodilation for the antihypertensive 
response to the calcium entry blocking agent nifedipine 
was investigated in 13 men with mild to moderate es•
sential hypertension. Blood pressure and systemic vas•
cular resistance were significantly reduced 30 minutes 
after sublingual administration of 10 mg of nifedipine 
while heart rate, cardiac index and plasma norepineph•
rine concentrations increased (all p < 0.01). Also, changes 
in mean blood pressure correlated inversely with arterial 
baroreflex sensitivity (r = - 0.74, P < 0.01), suggesting 
that arterial baroreflex mechanisms by means of sym•
pathetic activation tend to limit the acute antihyperten•
sive response. Blood pressure, but not systemic vascular 
resistance, decreased further (p < 0.01) after 6 weeks 
of therapy with nifedipine 20 mg three times daily, while 
Calcium entry blocking agents lower blood pressure effec•
tively and safely, both in hypertensive emergencies (1,2) 
and during long-term therapy of uncomplicated essential 
hypertension (3-5). Hemodynamically, they act as arterial 
vasodilators (3,6,7), thereby correcting increased systemic 
vascular resistance which characterizes the established phase 
of essential hypertension (8). Although the acute antihy•
pertensive response to calcium entry blockers is accompa•
nied by reflexly mediated tachycardia, neither increased heart 
rate nor volume retention seems to be of clinical importance 
during long-term therapy (3-7). This pattern differs mark•
edly from that observed with most other directly acting 
vasodilators because their long-term use leads to marked 
volume retention and reflex tachycardia (9), effects that 
usually preclude their use without concomitant administra•
tion of diuretic drugs and sympatholytic agents. To define 
further the role of sympathetic activity in the antihyperten-
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average heart rate, cardiac index and plasma norepi•
nephrine concentrations had returned toward pretreat•
ment values. 
Thus, a reduction of acutely increased sympathetic 
activity toward pretreatment values during long-term 
nifedipine therapy was associated with further decreases 
in blood pressure. The importance of sympathetic ac•
tivity was also stressed by the finding of an inverse re•
lation between chronic changes in heart rate and blood 
pressure (percent of control, r = - 0.76, P < 0.01). 
Blood volume did not change during long-term nifedi•
pine therapy. The results suggest that the degree ofsym•
pathetic reflex activation in part determines the anti•
hypertensive response to nifedipine monotherapy. 
(J Am Coli CardioI1986;7:344-8) 
sive response to calcium entry blockers we investigated 
hormonal and hemodynamic indexes of sympathetic acti•
vation as well as arterial baroreflex sensitivity during an•
tihypertensive therapy with the calcium entry blocker ni•
fedipine in patients with essential hypertension. 
Methods 
Patients. We investigated 13 male patients, aged 20 to 
60 years (mean 40.8), with newly diagnosed mild to mod•
erate hypertension. Adequately performed studies ruled out 
secondary causes of hypertension. Patients were informed 
of the investigational nature of the study, which had been 
approved by our hospital's Committee on the use of human 
subjects for clinical investigation. Written informed consent 
was obtained from all patients. 
Study design. The study was designed as a single-blind, 
placebo-controlled trial. Patients were given placebo tablets 
three times daily for 2 weeks, followed by 6 weeks of 
treatment with 20 mg of nifedipine, three times daily as 
slow release tablets. No other medications were allowed 
during the study period. Sodium intake was not controlled. 
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On the last day of the placebo and the treatment periods, 
respectively, hemodynamic studies were performed in the 
morning in a quiet air-conditioned room with the subjects 
recumbent and resting. All had refrained from tobacco and 
caffeinated beverages for at least 12 hours before study to 
avoid unwanted stimulation of sympathetic activity (10,11). 
For the second hemodynamic study, patients were instructed 
to take their morning dose of nifedipine at 7 AM and mea•
surements were obtained approximately 2'12 hours later. 
Systemic hemodynamics, arterial baroreflex sensitivity and 
venous plasma norepinephrine concentrations were deter•
mined at rest 30 minutes after placement of all catheters. 
During the placebo study, these measurements were re•
peated 30 minutes after sublingual administration of 10 mg 
of nifedipine. Blood volume was measured before and dur•
ing long-term therapy. 
Hemodynamic and catecholamine measurements. 
Details of the hemodynamic procedures utilized in this study 
have been reported elsewhere (6). In short, hemodynamic 
measurements were obtained with fluid-filled venous and 
arterial catheter systems using mid-chest as zero reference 
for pressure measurements. Mean blood pressure was ob•
tained by electronic dampening. Cardiac output was deter•
mined in duplicate by dye-dilution technique with injection 
of indocyanine green (10 mg) into the right atrium. Arterial 
dye concentration was measured in a brachial artery. Heart 
rate was obtained from the continuously recorded electro•
cardiogram. Blood volume was estimated as the volume of 
distribution of 5 mCi of iodine-131-labeled human serum 
albumin. Plasma norepinephrine concentrations were de•
termined using a radioenzymatic assay (12). 
Baroreflex sensitivity. Arterial baroreflex sensitivity was 
estimated by the ramp method as described by Smith et al. 
(13) using the modification of Bristow et al. (4). Phenyl-
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ephrine (starting dose 150 JLg) was injected into the right 
atrium to increase systolic pressure by at least 20 mm Hg. 
Arterial pressure and lead II of the electrocardiogram were 
monitored continuously before and during the injection. The 
slope of the regression line relating changes in systolic blood 
pressure to the RR interval of the electrocardiogram was 
calculated by the least squares method and taken as baro•
reflex sensitivity. Results were used for analysis only if the 
correlation coefficient (r) of a determination was greater than 
0.60 and the p value less than 0.05. All values represent 
the mean of at least two determinations. 
Statistical analysis. Group statistics represent mean val•
ues ± standard error of the means. Student's paired and 
unpaired t tests and linear regression analysis (least squares 
method) were employed where appropriate. 
Results 
The findings of the hemodynamic and hormonal inves•
tigations are summarized in Table 1. 
Acute findings. There was a modest yet significant acute 
reduction in systolic and diastolic pressure after nifedipine 
given sublingually. This decrease was associated with in•
creases in heart rate, cardiac index and plasma norepineph•
rine concentrations while calculated systemic vascular re•
sistance decreased, suggesting reflexly mediated sym•
pathoneural activation due to arterial vasodilation. Acute 
changes in plasma norepinephrine concentrations were di•
rectly related to changes in cardiac index (Fig. 1), and acute 
changes in pressure were inversely related to control baro•
reflex sensitivity (Fig. 2, upper panel). In addition, the latter 
was inversely related to age (Fig. 2, lower panel). 
Chronic findings. Blood pressure was reduced further 
after 6 weeks of oral therapy (range - 4.7 to - 38.7 mm 
Table 1. Summary of Hemodynamic and Hormonal Data in 13 Patients 
Blood pressure (mm Hg) 
SystolIc 
Diastolic 
Mean 
Heart rate (beats/min) 
Cardiac index (liters/min per m2) 
Systemic vascular resistance 
index (U/m2) 
Plasma catecholamine 
concentration (pg/ml) 
Norepinephnne 
Epinephrine 
Baroreflex sensitivity (ms/mm Hg) 
Control 
158 ± 4.7 
84 ± 4.1 
110.8 ± 5 5 
69.4 ± 3.7 
2.96 ± 0.25 
39.9 ± 37 
214 :±: 23 
47 :±: 9 
12.6 :±: 2.2 
Nifedipine 
10 mg s.1. 30 min 20 mg t.i.d. 6 weeks 
148 ± 4.7* 
78 ± 4.0* 
103.2 ± 5.2* 
81.6 ± 4.3t 
3.69 ± 0.3Jt 
29.7 ± 2.6t 
288 :±: 3lt 
50 :±: 6 
13.2 :±: 2.3 
138 ± 4.6§ 
72 ± 3.2§ 
91.4 ± 3.4§ 
72.1 ± 4.1§ 
320 ± 0.14t 
29.4 :±: 1.9 
240:±: 19:j: 
46 :±: 8 
12.0 :±: 2.4 
Values are reported as mean:±: SEM. The levels of significance of differences from nifedipine, 10 mg 
sublingually (s.I.), to control values (*p < 0.05, tp < 0.01, respectively) and from nifedlpine, 10 mg 
sublingually, to 6 weeks, 20 mg three times daily (t.i.d.) (:j:p < 005. §p < 0.01, respectively) are indicated. 
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Figure 1. Relation between acute changes in plasma norepineph•
rine (PNE) concentration and changes in cardiac index after sub•
lingual (s.l.) administration of nifedipine. Because one catechol•
amine sample was broken, only 12 subjects could be included in 
the analysis (r = 0.79; P < 0.01). 
Hg) (Table I). Despite this additional decrease, systemic 
vascular resistance had not decreased further as compared 
with the acute effect, and no correlation was found between 
changes in blood pressure and systemic vascular resistance. 
However, average heart rate, cardiac index and plasma nor•
epinephrine concentrations had decreased, and a significant 
inverse correlation was found between chronic changes in 
blood pressure and heart rate (Fig. 3). When patients were 
arbitrarily divided into responders (n = 8) and nonrespond•
ers (n = 5) on the basis of the chronic reduction in mean 
blood pressure (greater or less than 10% of control values), 
nonresponders (average decrease in mean pressure - 7.3 ± 
Figure 2. Relation between arterial baroreftex sensitivity and acute 
effects of nifedipine given sublingually (s.l.) on mean arterial 
pressure (upper panel) (n = 13; r = 0.74; P < 0.01). The lower 
panel shows the inverse correlation between baroreftex sensitivity 
and age (n = 13; r = -0.88; P < 0.01). 
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Figure 3. Relation between changes in heart rate and mean blood 
pressure (as percent of control values) during long-term antihy•
pertensive therapy with nifedipine (y = - 17.3 + 0.73 x; r = 
0.76; n = 13; P < 0.01). 
1.2 mm Hg) had a significantly greater increase in heart rate 
(Fig. 4) as compared with responders (average decrease in 
mean pressure - 19.3 ± 3.0 mm Hg). Chronic changes in 
systemic vascular resistance did not differ between groups. 
Baroreflex sensitivity and blood volume changes. 
Arterial baroreflex sensitivity remained unchanged during 
nifedipine therapy (Table 1), and control values correlated 
well with those found after nifedipine sublingually (r = 
0.84, P < 0.01) and during long-term oral therapy (r = 
0.72, p < 0.01), attesting to the reproducibility of the method. 
Blood volume did not change during therapy and no 
correlation was observed between either chronic changes in 
blood volume and blood pressure or between blood pressure 
and blood volume at 6 weeks. This was true when using 
Figure 4. Differing heart rate responses to long-term nifedipine 
therapy in eight responders (left column) and five nonresponders 
(right column). Responders were arbitrarily defined as patients 
whose mean arterial pressure decreased by more than 10% of the 
pretreatment value. **p < 0.01. 
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absolute 1::vels of blood volume for analysis or values cor•
rected for height or weight (15), 
Discussion 
In addition to confirming the antihypertensive potential 
of the calcium entry blocking agent nifedipine (3-7), our 
results provide information on the hemodynamic mecha•
nisms and reflex adjustments in short- and long-term nifed•
ipine therapy in essential hypertension, Nifedipine-induced 
decreases in blood pressure were characterized by arterial 
vasodilation, but chronic changes in blood pressure did not 
correlate with changes in vascular resistance, This obser•
vation indicates that factors other than the degree of vaso•
dilation were important for determining the antihypertensive 
response, There is evidence that different degrees of baro•
reflex activation and sympathetic stimulation may be of 
relevance in this respect. 
Determinants of antihypertensive response. The acute 
decrease in systemic vascular resistance after sublingual 
adminstration of nifedipine was associated with hemody•
namic and biochemical evidence of sympathetic activation 
as reflected by increases in heart rate, cardiac index and 
plasma norepinephrine concentrations, In addition, the de•
gree of sympathetic activation depends not only on the mag•
nitude of the stimulus (for example, arterial vasodilation), 
but also on the sensitivity of the baroreflex arch. Therefore, 
it was of interest to note that an inverse correlation existed 
between the sensitivity of the arterial baroreflexes and the 
acute antihypertensive response to nifedipine; patients whose 
baroreflexes were most responsive experienced the least acute 
blood pressure reduction and vice versa. The importance of 
sympathetic reflex activation is also emphasized by the cor•
relation between increases in plasma norepinephrine con•
centrations and cardiac index because an increase in cardiac 
index tends to overcome any antihypertensive drug effect. 
Taken together, these findings, therefore, suggest an im•
portant role of sympathetic reflex stimulation in the acute 
blood pressure response to nifedipine. 
During long-term therapy, blood pressure but not sys•
temic vascular resistance had decreased further as compared 
with the acute effect. In addition, on the average, heart rate, 
cardiac index and plasma norepinephrine concentrations had 
returned toward control values. The further decrease in blood 
pressure seen at 6 weeks, therefore, seemed to be mediated 
by a return toward control values of acutely increased sym•
pathetic activity. The importance of sympathetic activity for 
the chronic reduction in blood pressure is further supported 
by the findings of an inverse correlation between chronic 
changes in heart rate and blood pressure and a significantly 
greater chronic increase in heart rate in arbitrarily defined 
nonresponders. These observations are compatible with the 
contention that patients with a chronically elevated heart 
rate may still have some degree of sympathetic activation 
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and, therefore, experience a smaller decrease in blood pres•
sure as compared with patients whose heart rate and pre•
sumably sympathetic activity return to control or even below 
control values. Although our findings suggest that some 
degree of sympathetic activity persisted in nonresponders, 
it must be emphasized that absolute increases in heart rate 
were small and remained unnoticed by the patients. A sim•
ilar pattern suggestive of mild chronic sympathetic stimu•
lation was previously observed in a study using another 
dihydropyridine (nitrendipine) (16). In contrast, verapamil 
does not seem to cause acute or chronic reflex stimulation 
as judged by plasma norepinephrine measurements (17,18), 
findings which attest to the heterogeneity of this group of 
drugs. 
Barorefiex activation not only results in sympathetic 
stimulation, but also in reciprocal changes in parasympa•
thetic tone. Reduced parasympathetic inhibition may, there•
fore, have contributed bo\h to acute and chronic changes in 
heart rate in our patients. Because vagal tone was not mea•
sured in this study, we cannot exclude the possibility of 
differing degrees of vagal inhibition during long-term ther•
apy as an underlying cause for differing heart rate responses 
in responders and nonresponders. Animal experiments (19) 
also suggest that the extent of sympathetic and parasym•
pathetic stimulation after short-term therapy differs among 
the calcium entry blockers verapamil, diltiazem and nifed•
ipine. The relevance of parasympathetic stimulation with 
respect to treatment of human hypertension remains to be 
clarified. 
Pharmacokinetic differences between responders and 
nonresponders are an unlikely explanation for their differing 
heart rate responses because the hemodynamic stimulus for 
reflex activation (for example, changes in systemic vascular 
resistance) was similar in both groups during the second 
hemodynamic study. 
Differences in the response of intravascular volume could 
also determine the response to nifedipine. However, there 
was no volume retention or weight gain in this and other 
studies (3,4,17,18), and responders and nonresponders did 
not differ with respect to intravascular volume before and 
during therapy. Moreover, no correlation was found be•
tween intravascular volume and blood pressure during long•
term therapy as might be expected if intravascular volume 
and volume retention, respectively, were of importance for 
determining the chronic antihypertensive effect (20). The 
mechanisms responsible for the lack of volume retention 
with this type of arterial vasodilator have not been fully 
elucidated, but a diuretic effect (21) and interference with 
aldosterone secretion (16.22) have been suggested. 
Methodologic considerations. Several aspects of our 
study deserve further co~ment. First. changes in another 
widely used marker of sympathetic activity. namely, plasma 
norepinephrine concentration, did not correlate with changes 
in either blood pressure. heart rate or cardiac index during 
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long-term therapy. This could be explained by the fact that 
plasma norepinephrine concentrations are the result of a 
series of rather complex and not completely understood 
processes involving neuronal release, neuronal and extra•
neuronal reuptake and metabolism. The effects of calcium 
entry blocking agents on these mechanisms are not well 
investigated, but it has been found, for example, that ve•
rapamil reduces the neuronal release of norepinephrine in 
vitro (23), which may explain the clinical observation of a 
lack of plasma norepinephrine increase with this drug (17,18). 
Also, sympathetic activity is not distributed homogeneously 
throughout the body, and input from different circulatory 
sensing systems influences efferent sympathetic activity dif•
ferently in various parts of the circulation (24). Although 
arterial baroreflexes markedly influence the sympathetic 
control of the heart, most circulating norepinephrine may 
be derived from skeletal muscle. In other words, changes 
in cardiac sympathetic tone may not be truly reflected in 
the measurement of mixed peripheral norepinephrine con•
centrations (25). 
We do not know why the degree of sympathetic stimu•
lation seemed to differ between responders and nonrespond•
ers during long-term therapy. Although our findings suggest 
a resetting of arterial baroreflexes in responders, the mea•
surement of baroreflex sensitivity as performed in our study 
does not allow the determination of the setpoint of the ar•
terial baroreflexes and, therefore, does not add to our un•
derstanding in that regard. Overall arterial baroreflex sen•
sitivity did not change during therapy. This finding agrees 
with another recent study (26) describing a slight increase 
in baroreflex sensitivity during long-term nifedipine therapy. 
Normal or even improved function of arterial baroreflexes 
may be one of the factors contributing to the lack of or•
thostatic hypotension with nifedipine and other calcium en•
try blocking agents (5,7,26). 
Conclusions. Taken together, our data suggest that the 
degree of sympathetic reflex activation importantly deter•
mines the antihypertensive response to calcium entry block•
ade by nifedipine. 
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